Slide 1: CollabRx, Inc. - Informing Next Generation Healthcare
CollabRx, Inc. Informing Next Generation Healthcare
Slide 2: Forward-looking statements
This presentation and the accompanying commentary include forward-looking statements about CollabRx’ anticipated results that involve risks and uncertainties. Some of the information contained in this presentation, including, but not limited to, statements as to industry trends and CollabRx’ plans,
Slide 3: Agenda
¡ CollabRx’ Identity, Technology and Approach ¡ Platform for Knowledge Integration ¡ Products - Released and Under Development ¡ Healthcare Big Data Landscape ¡ Product Examples ¡ History, Management Team, Investment Thesis ¡ Contacts
Slide 4: Data Analytics Company, founded 2008
¡ Data Analytics Company, founded 2008 § NASDAQ CM: July 12, 2012 through merger ¡ Product-Driven, using a unique combination of Experts and Expert Systems to create a Proprietary Knowledgebase ¡ Inform clinical decision-making with up-to-date, actionable information on: § Biomarkers § Clinical Tria
Slide 5: Democratizing information by widely distributing KOL-based insights
¡ Democratizing information by widely distributing KOL-based insights ¡ “Agnostic” to any particular diagnostic test - focused on relevant biomarkers, therapies, drugs and trials ¡ Technology platform allows scaling in all dimensions as new biomarkers identified ¡ Easy-to-use apps are key to accessi
Slide 6: Knowledge Integration
KNOWLEDGE INTEGRATION Disease Targets Drugs Biomarkers Clinical Trials Basic Analytic Synthetic Capture and Integrate Acquire or License Create
Slide 7: Medical and scientific advisors and partners
Over 75 medical and scientific advisors from leading institutions "We're pleased to partner with CollabRx to leverage the Internet and social media to improve cancer treatment planning in melanoma and beyond.” “Our collaboration with CollabRx helps us deliver on our mission to serve patients and fos
Slide 8: Medical and Scientific Content, Software and IT, Tools and Services
Medical and Scientific Content Dynamically updated Best practice insights Clinically relevant interpretations Software and IT Content delivery systems (“apps”) Knowledge management systems Decision support dashboards Tools and Services Artificial intelligence-based analytics Interpretation of Big Da
Slide 9: Apps for Physician, Patient and Laboratory Teams
Physician / Patient Care Team Laboratory / Treatment Team Therapy Finder Apps Lung, Melanoma, Colorectal, Metastatic Breast, Prostate, Pancreatic, Acute Leukemia, Sarcoma (including GIST), GBE Clinical Trial Matching App Biomarker Reference Tool Interpretation Portal Path Lab App Molecular Diagnosti
Slide 10: Market opportunity and TAM
Annual: 750,000 tests* Ave. Price / Test ~ $3,000 Ave. Price / Report ~ $100-$200 TAM (today): $75M - $150M Growth Rate: ~47% pa** TAM (5 yr): $350M - $700M Pharma Pre-Launch Marketing budget per drug: ~ $50M # Number of Drugs in Pipeline for Common Incident Cancers ~ 50 % of Budget to On-Line 10% T
Slide 11: Revenue streams: subscription, license fees, advertising
Online Testing Labs Media ¢ Subscription ¢ License Fees ° Per Test e Ad Revenue Transaction Sharing Fees
Slide 12: Healthcare Big Data Landscape
Data Generation Data Interpretation Decision Influence Clinical Support Public Awareness Research Support Risk- Stratification Self-Care Enabler Caris Life Sciences Medicine Illumina Roche 454 Legend: Industry Segment Molecular Profiling / Dx Clinical Reference Predictive Analytics My Cancer Genome
Slide 13: Healthcare Big Data Landscape (CollabRx positioning)
Data Generation Data Interpretation Decision Influence Caris Life Clinical Support Public Awareness Research Support Risk- Stratification Self-Care Enabler Foundation Medicine Illumina Roche 454 Legend: Industry Segment Molecular Profiling / Dx Clinical Reference Predictive Analytics Compendia Biosc
Slide 14: Therapy Finders - Web Apps for Oncologists and Patients
Therapy Finders — Web Apps for Oncologists and Patients Individualized Lung Cancer Therapy Therapy Finder | About Therapy Finder | Progress in Treatment Therapy Finder - Professional Collab Molecular oncology indicates that many cancers are unique or part of Molecular testing may help identify an tr
Slide 15: Expert insights on targets, guidelines, drugs and trials
• Expert insights on: • Targets • Treatment Guidelines • Drugs • Trials • Literature • Links to: • Therapy Finder Advisor and Board • Learning About the Science Behind the Target . “
Slide 16: Content Engine
Content Engine Treating Physician Portal Patient Portal Test Result (e.g.,ION TORRENT) Drugs Clinical Trials
Slide 17: Life Technologies testimonial
“CollabRx has pioneered the development of a scalable platform and process to provide current, actionable, easily accessible, and highly credible knowledge at the point of care to aid physicians in developing a cancer treatment plan based on tumor molecular profiles. We are excited to include this k
Slide 18: Management Team
Tegal, IMTEC, Cresap, NSF American Medical Association, WebMD, Medscape Harvard Medical School (professor; molecular pathology) McKinsey & Company (GSK, Roche), MIT, UCSF PARC (XEROX), XEROX, MDL, UCSD ¡ Thomas Mika, Chairman & CEO § ¡ George Lundberg, MD, Editor-In-Chief § ¡ Gavin Gordon, MBA, PhD,
Slide 19: History and Investment Thesis
Approximately $10M Invested Capital Acquired by Tegal Corporation (TGAL) on July 12, 2012 Cash: $6.2M as of September 30, 2012 (Q2-FY’13) Liabilities: $0.5M Note to Sellers Net Operating Loss (Estimates): ~ $100M Federal; $50M California ~ 2 Million Total Shares Outstanding; ~2.6M fully-diluted ¡ Fo
Slide 20: Contact
tmika@collabrx.com 415.248.5350 (office) 415-686-2198 (mobile) CollabRx, Inc. 44 Montgomery St., Suite 800 San Francisco, CA 94104 www.collabrx.com NASDAQ CM: CLRX Thomas R. Mika, Chairman & CEO Investor Relations Contact: Robert Ferri Robert Ferri Partners 580 California Street, Suite 1200 San Fran